ID: ALA5085031

Max Phase: Preclinical

Molecular Formula: C28H28FN3O3

Molecular Weight: 473.55

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1ccc(C2(c3ccc(C)cc3)OC(=O)N3CCN(C(=O)NCc4ccc(F)cc4)CC32)cc1

Standard InChI:  InChI=1S/C28H28FN3O3/c1-19-3-9-22(10-4-19)28(23-11-5-20(2)6-12-23)25-18-31(15-16-32(25)27(34)35-28)26(33)30-17-21-7-13-24(29)14-8-21/h3-14,25H,15-18H2,1-2H3,(H,30,33)

Standard InChI Key:  BVEAAWPWYUNAHZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 473.55

Molecular Weight (Monoisotopic): 473.2115

AlogP: 4.73

#Rotatable Bonds: 4

Polar Surface Area: 61.88

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 5.08

CX LogD: 5.08

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.60

Np Likeness Score: -0.93

References

1. Albanese V, Ruzza C, Marzola E, Bernardi T, Fabbri M, Fantinati A, Trapella C, Reinscheid RK, Ferrari F, Sturaro C, Calò G, Amendola G, Cosconati S, Pacifico S, Guerrini R, Preti D..  (2021)  Structure-Activity Relationship Studies on Oxazolo[3,4-a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity.,  64  (7.0): [PMID:33733768] [10.1021/acs.jmedchem.0c02223]

Source

Source(1):

• Scientific Literature